Scholarlink

Introduction <p>Unresectable pancreatic cancer has the lowest 5&#xa0;year relative survival rate among all cancers, at approximately 10%. Standard treatments are often limited because of severe toxicities, and therefore long-term treatment is challenging. We report a case of unresectable pancreatic cancer with a <i>BRCA</i> gene mutation achieving long-term survival through modified FOLFIRINOX (mFFX) therapy.</p> Case presentation <p>A 61-year-old male was diagnosed with unresectable pancreatic head cancer, accompanied by liver metastasis and para-aortic lymph node metastasis. Initial treatment with gemcitabine and nab-paclitaxel resulted in progressive disease, prompting a switch to mFFX. The first evaluation of efficacy showed significant shrinkage of both the primary tumor and metastatic lesions, and the second evaluation confirmed a complete response. After <i>BRCA</i> gene testing became eligible for insurance coverage, a <i>BRCA</i>2 gene mutation was identified. The patient continued treatment with drugs except oxaliplatin. Lung metastasis appeared and was treated with local therapy. Seven years have passed since the start of treatment, and the patient continues to receive treatment without significant side effects.</p> Conclusions <p>We present a case of unresectable pancreatic cancer with a <i>BRCA</i> germline mutation that was treated with a combination treatment and achieved long-term survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy

  • 期刊论文

  • 发表日期：

    2026年5月18日

查看全文
  • Keita Takahashi,
  • Rumi Itoyama,
  • Takanobu Yamao,
  • Teruo Sako,
  • Yuki Hisano,
  • Yuki Kitano,
  • Shigeki Nakagawa,
  • Hirohisa Okabe,
  • Hiromitsu Hayashi,
  • Masaaki Iwatsuki

摘要

Introduction

Unresectable pancreatic cancer has the lowest 5 year relative survival rate among all cancers, at approximately 10%. Standard treatments are often limited because of severe toxicities, and therefore long-term treatment is challenging. We report a case of unresectable pancreatic cancer with a BRCA gene mutation achieving long-term survival through modified FOLFIRINOX (mFFX) therapy.

Case presentation

A 61-year-old male was diagnosed with unresectable pancreatic head cancer, accompanied by liver metastasis and para-aortic lymph node metastasis. Initial treatment with gemcitabine and nab-paclitaxel resulted in progressive disease, prompting a switch to mFFX. The first evaluation of efficacy showed significant shrinkage of both the primary tumor and metastatic lesions, and the second evaluation confirmed a complete response. After BRCA gene testing became eligible for insurance coverage, a BRCA2 gene mutation was identified. The patient continued treatment with drugs except oxaliplatin. Lung metastasis appeared and was treated with local therapy. Seven years have passed since the start of treatment, and the patient continues to receive treatment without significant side effects.

Conclusions

We present a case of unresectable pancreatic cancer with a BRCA germline mutation that was treated with a combination treatment and achieved long-term survival.